AKT1 and malignant glioma: The rationale for selecting a PI-3kinase inhibitor as an effective therapeutic agent for the treatment of malignant gliomas is based on the fact that the PI-3kinase/AKT pathway is critical in the pathogenesis and progression of malignant gliomas [18,39,40].